Zomedica Pretax Profit Margin from 2010 to 2024

ZOM Stock  USD 0.12  0  3.08%   
Zomedica Pharmaceuticals Pretax Profit Margin yearly trend continues to be very stable with very little volatility. Pretax Profit Margin is likely to drop to -1.49. During the period from 2010 to 2024, Zomedica Pharmaceuticals Pretax Profit Margin quarterly data regression pattern had range of 3.9884 and standard deviation of  1.53. View All Fundamentals
 
Pretax Profit Margin  
First Reported
2010-12-31
Previous Quarter
(1.42)
Current Value
(1.49)
Quarterly Volatility
1.53478517
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Zomedica Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Zomedica Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 183.8 K, Selling General Administrative of 30.5 M or Other Operating Expenses of 59.6 M, as well as many indicators such as Price To Sales Ratio of 7.4, Dividend Yield of 0.0 or PTB Ratio of 0.78. Zomedica financial statements analysis is a perfect complement when working with Zomedica Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Zomedica Pharmaceuticals Correlation against competitors.

Latest Zomedica Pharmaceuticals' Pretax Profit Margin Growth Pattern

Below is the plot of the Pretax Profit Margin of Zomedica Pharmaceuticals Corp over the last few years. It is Zomedica Pharmaceuticals' Pretax Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Zomedica Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Pretax Profit Margin10 Years Trend
Slightly volatile
   Pretax Profit Margin   
       Timeline  

Zomedica Pretax Profit Margin Regression Statistics

Arithmetic Mean(4.27)
Coefficient Of Variation(35.92)
Mean Deviation1.18
Median(5.01)
Standard Deviation1.53
Sample Variance2.36
Range3.9884
R-Value0.69
Mean Square Error1.34
R-Squared0.47
Significance0
Slope0.24
Total Sum of Squares32.98

Zomedica Pretax Profit Margin History

2024 -1.49
2023 -1.42
2022 -1.02

About Zomedica Pharmaceuticals Financial Statements

Zomedica Pharmaceuticals investors utilize fundamental indicators, such as Pretax Profit Margin, to predict how Zomedica Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Pretax Profit Margin(1.42)(1.49)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Zomedica Pharmaceuticals is a strong investment it is important to analyze Zomedica Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zomedica Pharmaceuticals' future performance. For an informed investment choice regarding Zomedica Stock, refer to the following important reports:
Check out the analysis of Zomedica Pharmaceuticals Correlation against competitors.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.06)
Revenue Per Share
0.027
Quarterly Revenue Growth
0.018
Return On Assets
(0.09)
Return On Equity
(0.24)
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.